Xponance Inc. raised its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 6.9% during the fourth quarter, ...
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the ...
Results were announced from a trial evaluating durvalumab with FLOT chemo as perioperative treatment for resectable early stage gastric/GEJ cancers.
Clinical Trials Arena on MSN3d
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancerThe company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback